X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

06 Feb 2025 06:35:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

24 Jan 2025 06:36:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

13 Jan 2025 06:35:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

04 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 05:07:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

13 Nov 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

08 Aug 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

27 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2024 15:05:00 By Nasdaq GlobeNewswire